Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 106. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Use of artificial intelligence to enhance detection of nodal metastases857
SABR for operable stage I non-small-cell lung cancer: comparison to surgery603
Patients with cancer in Louisiana denied fertility preservation cover540
Combination immunotherapy in chemotherapy in gastric cancer516
US FDA proposes stronger laboratory test oversight466
Correction to Lancet Oncol 2022; 23: 1124–26418
Enhancing equity and long-term impact assessments in radiotherapy environmental studies399
IVLBCL mimicking VEXAS syndrome397
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer376
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy365
The GLOW trial in chronic lymphocytic leukaemia357
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer316
Dual therapy in metastatic castration-resistant prostate cancer312
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer311
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply311
Study bolsters concerns about US FDA accelerated drug approvals308
Olanzapine for chemotherapy-induced nausea and vomiting control306
CAR T cells for the long run in aggressive B-cell lymphoma288
Correction to Lancet Oncol 2021; 22: 1081–92284
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC279
Antibody–drug conjugates in acute myeloid leukaemia: more research needed279
The future of precise cancer chronotherapeutics265
A new generation of comprehensive precision oncology trials261
Survivorship after neoadjuvant chemotherapy252
Italy to pass law on the right to be forgotten for cancer survivors250
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply240
SANO trial: innovations, risks, and unanswered questions238
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation235
Palliative radiotherapy for hepatic cancer pain224
Concern for cancer drugs in USA–EU tariff war224
US Surgeon General calls for cancer warning labels on alcohol218
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries215
Innovation in gynaecological cancer: highlighting global disparities211
Determining the optimal use of approved drugs in oncology209
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia208
Precision medicine for children with cancer206
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies199
Health insurance system in Japan faces risk of politicisation196
Navigating the complexity: reflections on the development of perioperative cancer treatments194
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 193
The silent malignant mesothelioma epidemic: a call to action193
Medical treatment for active breast cancer brain metastases191
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t188
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm187
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial184
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial183
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis182
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges181
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial180
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult179
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial175
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery172
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study172
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi168
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, 168
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study167
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 165
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial163
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply160
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX159
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus156
New national cancer registry for France155
Focus where it matters: turning insights into advocacy154
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study151
A biobank perspective on use of tissue samples donated by trial participants149
Common Sense Oncology: including everyone148
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer148
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply147
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?147
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply146
Essential anticancer medicines for children: defining what matters most for Europe145
Importance of clinical research for the UK's 10-year cancer plan140
Radiotherapy with genomic-adjusted radiation dose139
Radiotherapy with genomic-adjusted radiation dose139
Mantle cell lymphoma: is it time for risk-adapted treatment?139
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire138
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer137
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus136
Lung cancer rates highest among British Bangladeshi men134
Antimicrobial resistance in patients with haematological malignancies: a scoping review133
WHO reports health service disruptions due to suspensions of aid132
Balancing clinical benefit and social value: challenges in HTA assessments130
Decentralised, point-of-care CAR-T for multiple myeloma130
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study127
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo126
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group123
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti123
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study123
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup121
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer118
Cancer on the agenda during IAEA Director General's visit to Chile118
Challenges and prospects for cancer treatment in prison settings116
Daratumumab maintenance in patients with myeloma116
Correction to Lancet Oncol 2020; 21: 699–709115
Correction to Lancet Oncol 2023; 24: e242115
2022 ASTRO annual meeting114
Clearing the radiotherapy backlog: innovation to pave the way114
Radiotherapy and conflict: from disruption to expansion and hope112
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit112
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA111
Shortages of essential medications for children with cancer in Colombia111
A growing vulvar mass in a post-menopausal woman111
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations110
Syrian cancer patients regain treatment access in Türkiye108
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer108
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial106
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update106
0.09343409538269